Bli medlem
Bli medlem

Du är här


aap: Q1/2016 sales and EBITDA in line with expectations

ith expectations.
Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is
solely responsible for the content of this announcement.
Implantate AG ("aap"
) achieved in the first quarter of 2016 sales and EBITDA at the group level in
line with the guidance. Sales in the reporting period totalled EUR 5.1
million (Q1/2015: EUR 7.1 million) and were thus within the forecast
published in February 2016 of EUR 4.5 million to EUR 6.0 million. For the
first quarter of 2016 the company posted an EBITDA of EUR -1.9 million
(Q1/2015: EUR 0.2 million) that was also within the forecasted corridor of
EUR -2.0 million to EUR -1.0 million.

Deteriorated macroeconomic developments in BRICS and SMIT countries negatively influenced our planned sales development in the last year and presented a challenge in the first quarter of 2016 as well. This is characterized by the fact that markets as China, Turkey and Russia did not contribute to the sales in the first quarter.aap
has reacted to this and focussed increasingly on established markets and already initiated necessary sales activities in these markets. Overall the company expects the measures to become effective in the second half of 2016.

| In EUR million Q1/2016 Q1/2015 Change on year |
| Trauma 2.2 2.6 -16% |
| Other 0.3 0.3 -3% |
| Sales continued operation 2.5 2.9 -14% |
| |
| Sales discontinued operation 2.6 4.2 -39% |
| Group sales 5.1 7.1 -29% |

| In EUR million Q1/2016 Q1/2015 Change on year |
| Group EBITDA -1.9 0.2 >-100% |
| EBITDA discontinued operation 0.3 2.0 -85% |
| EBITDA continued operation -2.2 -1.8 -23% |

In the continued operationaap
generated sales in the first quarter of 2016 of EUR 2.5 million (Q1/2015: EUR 2.9 million). The company's sales in the discontinued operation amounted to EUR 2.6 million (Q1/ 2015: EUR 4.2 million) in the reporting period.
EBITDA in the continued operation totalled EUR -2,2 million (Q1/2015: EUR -1.8 million) in the first three months of the current financial year. In the discontinued operationaap
realized EBITDA of EUR 0.3 million (Q1/2015: EUR 2.0 million) in the first quarter of 2016.
The following highlights show the progress thataap
made in implementing its 2016 Management Agenda in the first quarter of 2016:
* Signing of a share purchase agreement for the sale of 100% of the company
shares inaap Biomaterials GmbH on 22 March 2016; the transaction was closed
on 11 May 2016
* LOQTEQ®: Progress on schedule in completing the LOQTEQ® product portfolio;
focus of research and development activities on implants for lower
extremities and the launch of the periprosthetic treatment system
* Silver coating technology: Submission of design dossier for CE conformity
assessment procedure at a notified body in January 2016; first steps in the
approval process by the US Food and Drug Administration (FDA) undertaken

Outlook for 2016

In the second quarter of 2016aap
aims to achieve further progress in its strategy implementation. The Management Board will be focussing on the following topics:
To accelerate value-based innovationsaap
will be taking forward in a targeted manner the further expansion of the LOQTEQ® portfolio for certain indication areas respectively functionalities. In the area of silver coating technology an active interaction with the approval authorities is to be pursued for the approval process under way.
The company wants to enhance market access by means of two approaches: Firstly, sales activities in the established markets in Western Europe as well as in the United States are to be expanded further. Secondly, further endeavours are to be undertaken to stabilize sales in growth markets such as the BRICS and SMIT countries.
Following the successful divestment ofaap
Biomaterials GmbH,aap
will in the second quarter also be concentrating on optimizing operational efficiency with a focus on adjusting the cost structure to the company's new size.
According to preliminary calculations, the completion of theaap
Biomaterials GmbH transaction will result in a positive one-time overall effect on the earnings level of about EUR 19.6 million in the second quarter of 2016.
Thus the Management Board confirms its forecast for the entire year of 2016: The company anticipates for the EDITDA of the Group (continued and discontinued operation) incl. deconsolidation gain a value of between EUR 14.1 million and EUR 15.7 million.
For the continued operation sales between EUR 13.0 million and EUR 15.0 million and an EBITDA between EUR -5.5 million and EUR -3.9 million are expected.
For the second quarter of 2016,aap
is expecting for the continued operation sales to range between EUR 2.5 million and EUR 3.5 million and an EBITDA of EUR -2.0 million to EUR -1.5 million.
Implantate AG

aap Implantate AG is a globally operating medical device company headquartered
in Berlin, Germany. The company develops, manufactures and markets trauma and
biomaterials products for orthopedics. The trauma portfolio includes besides
the innovative anatomical plating system LOQTEQ® a wide range of cannulated
screws as well as standard plates and screws. In the biomaterials business
the company is specialized on bone cements and mixing systems. In
German-speaking countriesaap
Implantate AG directly sells its trauma products to hospitals, buying
syndicates and hospital groups while it uses a broad network of distributors
in more than 60 countries at the international level. In the biomaterials
business sales are handled via OEM and private label cooperations with
several selected international orthopedic and trauma companies.aap
Implantate AG's stock is listed in the Prime Standard segment of Frankfurt
Stock Exchange (XETRA: AAQ.DE). For more information, please visit, or download the Company's investor relations app from the Apple's
App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current
experience, estimates and projections of the management board and currently
available information. They are not guarantees of future performance. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. Many
factors could cause the actual results, performance or achievements of aap to
be materially different from those that may be expressed or implied by such
statements. These factors include those discussed inaap
's public reports. Forward-looking statements therefore speak only as of the
date they are made.aap
does not assume any obligation to update the forward-looking statements
contained in this release or to conform them to future events or

For inquiries please contact:aap
Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin,

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail:


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aap Implantate AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.